Jake VanCampen

Jake VanCampen

Auto-generated profile, based on publicly available information

Jake VanCampen

Department of Chemistry, University of Portland, Portland, Oregon, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2023 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
WYWilliam M. Yashar
William M. Yashar
BCBrittany M. Curtiss
Brittany M. Curtiss
DCDaniel J. Coleman
Daniel J. Coleman
JVJake VanCampen
Jake VanCampen
GKGarth Kong
Garth Kong
TBTheodore P. Braun
Theodore P. Braun
Mutations in Fms-like tyrosine kinase 3 (FLT3) are common drivers in acute myeloid leukemia (AML) yet FLT3 inhibitors only provide modest clinical benefit. Prior work has shown that inhibitors of lysine-specific demethylase 1 (LSD1) enhance kinase inhibitor activity in AML. Here we show that combined LSD1 and FLT3 inhibition induces synergistic cell death in FLT3-mutant AML. Multi-omic profiling revealed that the drug combination disrupts STAT5, LSD1, and GFI1 binding at the MYC blood superenhancer, suppressing superenhancer accessibility as well as MYC expression and activity. The drug combination simultaneously results in the accumulation of repressive H3K9me1 methylation, an LSD1 substrate, at MYC target genes. We validated these findings in 72 primary AML samples with the nearly every sample demonstrating synergistic responses to the drug combination. Collectively, these studies reveal how epigenetic therapies augment the activity of kinase inhibitors in FLT3-ITD (internal tandem duplication) AML. Implications: This work establishes the synergistic efficacy of combined FLT3 and LSD1 inhibition in FLT3-ITD AML by disrupting STAT5 and GFI1 binding at the MYC blood-specific superenhancer complex.

23 October 2024 in Journal of Biological Chemistry
Verified
Journal Article
Open access
APAlec Peters
Alec Peters
FBFatima Banine
Fatima Banine
KYKanon Yasuhara
Kanon Yasuhara
AHAngela Hoffman
Angela Hoffman
BABasappa
Basappa
LSLarry S. Sherman
Larry S. Sherman
Growing evidence supports pathogenic roles for chronically elevated hyaluronidase activity in numerous conditions. Elevated expression of one such hyaluronidase, the Cell Migration Inducing and hyaluronan binding Protein (CEMIP), has been implicated in the pathogenesis and progression of several cancers as well as demyelinating diseases in the central nervous system (CNS). Developing effective and selective CEMIP inhibitors could therefore have efficacy in treating a variety of conditions where CEMIP is chronically elevated. Using two distinct screens for novel hyaluronidase inhibitors, we identified two synthetic thiocarbamates and one plant-derived flavonoid, sulfuretin, that effectively blocked CEMIP activity in live cells, including a tumorigenic cell line and primary cultures of oligodendrocyte progenitor cells (OPCs). None of these agents influenced cell proliferation, but they had differential dose-dependent and cell type-specific effects on cell survival. Furthermore, we found that each of these agents could promote oligodendrocyte maturation by OPCs in the presence of high molecular weight (>2 Mda) hyaluronan, the accumulation of which is linked to the inhibition of OPC maturation and remyelination failure in demyelinating diseases. These findings indicate that CEMIP can be inhibited through distinct chemical interactions and that CEMIP inhibitors have potential efficacy for treating demyelinating diseases or other conditions where CEMIP is elevated.

12 January 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
WYWilliam M Yashar
William M Yashar
GKGarth Kong
Garth Kong
JVJake VanCampen
Jake VanCampen
BSBrittany M Smith
Brittany M Smith
DCDaniel J Coleman
Daniel J Coleman
TBTheodore P Braun
Theodore P Braun
Genome-wide mapping of the histone modification landscape is critical to understanding tran-scriptional regulation. Cleavage Under Targets and Tagmentation (CUT&Tag) is a new method for profiling the localization of covalent histone modifications, offering improved sensitivity and decreased cost compared with Chromatin Immunoprecipitation Sequencing (ChIP-seq). Here, we present GoPeaks, a peak calling method specifically designed for histone modification CUT&Tag data. GoPeaks implements a Binomial distribution and stringent read count cut-off to nominate candidate genomic regions. We compared the performance of GoPeaks against commonly used peak calling algorithms to detect H3K4me3, H3K4me1, and H3K27Ac peaks from CUT&Tag data. These histone modifications display a range of peak profiles and are frequently used in epigenetic studies. We found GoPeaks robustly detects genome-wide histone modifications and, notably, identifies H3K27Ac with improved sensitivity compared to other standard peak calling algorithms.

16 September 2024
Verified
Other
Open access
WYWilliam M. Yashar
William M. Yashar
BCBrittany M. Curtiss
Brittany M. Curtiss
DCDaniel J. Coleman
Daniel J. Coleman
JVJake VanCampen
Jake VanCampen
GKGarth Kong
Garth Kong
TBTheodore P. Braun
Theodore P. Braun
Dual FLT3/LSD1 inhibition suppresses MYC expression and activity.

16 September 2024
Verified
Other
Open access
WYWilliam M. Yashar
William M. Yashar
BCBrittany M. Curtiss
Brittany M. Curtiss
DCDaniel J. Coleman
Daniel J. Coleman
JVJake VanCampen
Jake VanCampen
GKGarth Kong
Garth Kong
TBTheodore P. Braun
Theodore P. Braun
Transcription Factor Enrichment Analysis of Primary AML Bulk RNA-Seq (24 Hours After Drug Treatment)

16 September 2024
Verified
Other
Open access
WYWilliam M. Yashar
William M. Yashar
BCBrittany M. Curtiss
Brittany M. Curtiss
DCDaniel J. Coleman
Daniel J. Coleman
JVJake VanCampen
Jake VanCampen
GKGarth Kong
Garth Kong
TBTheodore P. Braun
Theodore P. Braun
Efficacy of dual FLT3/LSD1 inhibition in primary AML samples.